{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:27:53Z","timestamp":1789079273577,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaad.2026.01.076","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:08:01Z","timestamp":1779883681000},"page":"S14-S20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Beyond T helper 2 cells: Integrating immune, barrier, microbial, and neuroimmune pathways in atopic dermatitis pathogenesis"],"prefix":"10.1016","volume":"94","author":[{"given":"Jerry","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.01.076_bib1","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0091-6749(99)70051-5","article-title":"Pathogenesis of atopic dermatitis","volume":"104","author":"Leung","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaad.2026.01.076_bib4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jaad.2026.01.076_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2133.1974.tb06447.x","article-title":"Staphylococcus aureus in the lesions of atopic dermatitis","volume":"90","author":"Leyden","year":"1974","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1172\/JCI116711","article-title":"Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. evidence for a new group of allergens","volume":"92","author":"Leung","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2026.01.076_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib8","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2026.01.076_bib9","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-025-59340-x","article-title":"An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis","volume":"16","author":"Fukushima-Nomura","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaad.2026.01.076_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for treatment of atopic dermatitis: current status and future prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2026.01.076_bib12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2026.01.076_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jaci.2009.09.031","article-title":"Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis","volume":"124","author":"Guttman-Yassky","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib17","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of Th2\/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is T(H)2\/T(H)22-skewed with T(H)1\/T(H)17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2022.12.050","article-title":"Proteomic characterization of atopic dermatitis blood from infancy to adulthood","volume":"88","author":"Del Duca","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib23","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","article-title":"Early-onset pediatric atopic dermatitis is characterized by T(H)2\/T(H)17\/T(H)22-centered inflammation and lipid alterations","volume":"141","author":"Brunner","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib24","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2026.01.076_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2026.01.076_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis","volume":"152","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","article-title":"Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials","volume":"93","author":"Gooderham","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib29","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms24031813","article-title":"Increased serum levels of tumor necrosis factor-like ligand 1A in atopic dermatitis","volume":"24","author":"Hisamoto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2026.01.076_bib30","doi-asserted-by":"crossref","first-page":"i79","DOI":"10.1093\/ecco-jcc\/jjae190.0039B","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.jaad.2026.01.076_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of Anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/derm.2024.0058","article-title":"The role of OX40-OX40L axis in the pathogenesis of atopic dermatitis","volume":"36","author":"Schettini","year":"2025","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2026.01.076_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","article-title":"OX40 in the pathogenesis of atopic Dermatitis-A new therapeutic target","volume":"25","author":"Croft","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/bjd\/ljae230","article-title":"The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis","volume":"191","author":"Guttman-Yassky","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib36","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3452","article-title":"The OX40 axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2026.01.076_bib37","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.3390\/jcm13226925","article-title":"Anti-OX40 biological therapies in the treatment of atopic dermatitis: a comprehensive review","volume":"13","author":"Marfil-Cant\u00f3n","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib38","article-title":"Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis","volume":"3","author":"Rewerska","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaad.2026.01.076_bib39","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1007\/s13555-024-01303-z","article-title":"Rocatinlimab improves patient-reported outcomes in adults with moderate-to-severe atopic dermatitis: results from a double-blind placebo-controlled phase 2b study","volume":"14","author":"Gooderham","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2026.01.076_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/1750743X.2025.2464528","article-title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis","volume":"17","author":"Guttman-Yassky","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaad.2026.01.076_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.076","article-title":"702-IMG-007, a nondepleting OX40 monoclonal antibody with an extended half-life, improves skin lesions in adults with moderate-to-severe atopic dermatitis: interim results from a phase 2a trial","volume":"191","author":"Shen","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.037","article-title":"658-IMG-007, a novel nondepleting anti-OX40 monoclonal antibody with Fc bioengineering, exhibited reduced safety risks: evidence from nonclinical studies","volume":"191","author":"Guo","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib43","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.anai.2023.08.275","article-title":"Safety and pharmacokinetics of IMG-007, an OX40 monoclonal antibody, in healthy adults","volume":"131","author":"Shen","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib44","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","article-title":"Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis","volume":"155","author":"Weidinger","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2026.01.076_bib45","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/jdv.20877","article-title":"Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab","volume":"39","author":"Blauvelt","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2026.01.076_bib47","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaci.2012.12.1566","article-title":"Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin","volume":"131","author":"Pellerin","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib48","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.jaip.2020.03.048","article-title":"Events in normal skin promote early-life atopic dermatitis-the MPAACH cohort","volume":"8","author":"Biagini Myers","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2026.01.076_bib49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/all.13223","article-title":"Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues","volume":"72","author":"Brunner","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2026.01.076_bib50","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1111\/all.15423","article-title":"Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation","volume":"77","author":"Renert-Yuval","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2026.01.076_bib51","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2020.01.042","article-title":"Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis","volume":"145","author":"He","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib52","first-page":"281","article-title":"OX40\/OX40L as a therapeutic target in atopic dermatitis: a scoping review","volume":"19","author":"Valenzuela","year":"2025","journal-title":"Biologics"},{"issue":"12","key":"10.1016\/j.jaad.2026.01.076_bib53","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","article-title":"OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab","volume":"14","author":"L\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jaad.2026.01.076_bib54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00403-024-03426-x","article-title":"Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab","volume":"316","author":"Guttman-Yassky","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2026.01.076_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2026.01.076_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2026.01.076_bib58","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.immuni.2025.03.018","article-title":"The sensory neuroimmune frontier","volume":"58","author":"Kim","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2026.01.076_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.immuni.2020.10.001","article-title":"Substance P release by sensory neurons triggers dendritic cell migration and initiates the Type-2 immune response to allergens","volume":"53","author":"Perner","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2026.01.076_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2026.01.076_bib61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1684\/ejd.2017.2985","article-title":"Expression of keratin 1, keratin 10, desmoglein 1 and desmocollin 1 in the epidermis: possible downregulation by interleukin-4 and interleukin-13 in atopic dermatitis","volume":"27","author":"Totsuka","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2026.01.076_bib62","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.3390\/ijms21155382","article-title":"Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2026.01.076_bib63","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000331871","article-title":"IL-25 induces both inflammation and skin barrier dysfunction in atopic dermatitis","volume":"96","author":"Deleuran","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaad.2026.01.076_bib65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.06.014","article-title":"Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis","volume":"134","author":"Thyssen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaci.2016.06.002","article-title":"Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march","volume":"138","author":"Egawa","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib67","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1194\/jlr.P030338","article-title":"Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients","volume":"53","author":"Janssens","year":"2012","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.jaad.2026.01.076_bib68","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3390\/ijms23042121","article-title":"Atopic dermatitis: the fate of the fat","volume":"23","author":"Pavel","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2026.01.076_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2433","article-title":"Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis","volume":"339","author":"van den Oord","year":"2009","journal-title":"Bmj"},{"key":"10.1016\/j.jaad.2026.01.076_bib70","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/all.15569","article-title":"Dysregulated lipidome of sebum in patients with atopic dermatitis","volume":"78","author":"Yin","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2026.01.076_bib71","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib72","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","article-title":"Emerging biologic therapies for the treatment of atopic dermatitis","volume":"84","author":"Alvarenga","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2026.01.076_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.07.951","article-title":"53111 Individual patient responses to IL-22RA1 inhibition in a phase 2a monotherapy trial for moderate-to-severe atopic dermatitis","volume":"91","author":"Gooderham","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","article-title":"Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review","volume":"154","author":"Silverberg","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2024.1323405","article-title":"Aryl hydrocarbon receptor and IL-13 signaling crosstalk in human keratinocytes and atopic dermatitis","volume":"5","author":"Proper","year":"2024","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaad.2026.01.076_bib77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition","volume":"28","author":"Guttman-Yassky","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib79","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","article-title":"Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials","volume":"160","author":"Simpson","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib80","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaci.2025.07.025","article-title":"IL-18 in atopic dermatitis-a multifaceted driver of skin inflammation","volume":"156","author":"B\u00e4hler","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib83","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.apsb.2024.09.008","article-title":"Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer","volume":"14","author":"Feng","year":"2024","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.jaad.2026.01.076_bib84","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s13555-025-01505-z","article-title":"Efficacy and safety of zabedosertib, an Interleukin-1 receptor-associated kinase 4 inhibitor, in patients with moderate-to-severe atopic dermatitis: a phase II randomized study","volume":"15","author":"Jodl","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2026.01.076_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaci.2018.11.015","article-title":"The microbiome in patients with atopic dermatitis","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib87","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib88","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/jid.2008.74","article-title":"Th2 cytokines act on S100\/A11 to downregulate keratinocyte differentiation","volume":"128","author":"Howell","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.04.029","article-title":"Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification","volume":"154","author":"H\u00fclp\u00fcsch","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00277-24","article-title":"Skin microbiota in atopic dermatitis: victim or executioner?","volume":"38","author":"Boggio","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2026.01.076_bib91","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","article-title":"Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship","volume":"26","author":"Geoghegan","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jaad.2026.01.076_bib92","article-title":"Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli","volume":"3","author":"Lebeer","year":"2022","journal-title":"Cel Rep Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102002","article-title":"Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial","volume":"60","author":"Silverberg","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaad.2026.01.076_bib94","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaci.2015.07.052","article-title":"Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis","volume":"137","author":"Tauber","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.01.076_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000532054","article-title":"A randomized, double-blind, placebo-controlled, multicenter, 16-Week trial to evaluate the efficacy and safety of FB-401 in children, adolescents, and adult subjects (ages 2 years and older) with mild-to-moderate atopic dermatitis","volume":"240","author":"Jacobson","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2026.01.076_bib96","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2020.08.132","article-title":"Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial","volume":"86","author":"Niemeyer-van der Kolk","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.01.076_bib97","article-title":"Interventions to reduce Staphylococcus aureus in the management of eczema","volume":"2019","author":"George","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2026.01.076_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.790","article-title":"Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Weiss","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jaad.2026.01.076_bib99","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","article-title":"IL-4R\u03b1 blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis","volume":"140","author":"Callewaert","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","article-title":"Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial","volume":"88","author":"Beck","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.01.076_bib101","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/bjd\/ljaf095","article-title":"Upadacitinib outperforms dupilumab in restoring the fungal microbiome in atopic dermatitis","volume":"193","author":"Li","year":"2025","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:58:17Z","timestamp":1781715497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0190962226001283"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.076","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond T helper 2 cells: Integrating immune, barrier, microbial, and neuroimmune pathways in atopic dermatitis pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.01.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}